Market Overview

Receptos Up 8%; Wedbush Sees Possible Takeover

Related RCPT
UPDATE: Receptos Posts Wider Q4 Loss
Receptos Gains 2%, CEO Touts Phase II Trials
AbbVie's high-priced takeout of Pharmacyclics bodes well for other biotechs with high potential drugs (Seeking Alpha)

Receptos (NASDAQ: RCPT) closed Monday just short of a 52-seek high after an analyst suggested the drug development company could become a takeover candidate.

Receptos is developing drugs for a range of immune system disorders including its lead product for multiple sclerosis and inflammatory bowel disease.

Wedbush's Liana Mousatos, who reiterated an Outperform rating and $63 target, said a conference slated for September 10 in Boston could become a venue for the company to unveil positive data from current drug trials.

Mousatos expects a Phase II trial of its treatment for inflammation of the esophagus to launch in the second half of 2014 along with release of interim results from a trial of its colitis drug.

Receptos closed Monday at $50.69, up 8.24 percent.

Latest Ratings for RCPT

Jan 2015Evercore PartnersInitiates Coverage onBuy
Nov 2014NomuraMaintainsBuy
Oct 2014NomuraMaintainsBuy

View More Analyst Ratings for RCPT
View the Latest Analyst Ratings

Posted-In: Liana MousatosAnalyst Color News Price Target Reiteration FDA After-Hours Center Analyst Ratings


Related Articles (RCPT)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Benzinga PRO content